BioPharma Clinical Trials

EMA grants Orphan Drug Designation to GC Biopharma's Sanfilippo Syndrome (Type A) Treatment

GC1130A has previously achieved notable milestones by securing both Rare Pediatric Disease designation (RPDD) and Orphan Drug Designation (ODD) from the U....

 January 24, 2024 | News

AIM ImmunoTech Initiates Phase 1b/2 Trial for Ampligen® and AstraZeneca's Imfinzi® in Late-Stage Pancreatic Cancer

 AIM ImmunoTech Inc. announced that the first subject has been enrolled at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIM&rs...

 January 23, 2024 | News

NK CellTech Announces FDA Clearance for Clinical Trial of NK010

NK010 exhibits multiple high anti-tumor advantages including wide spectrum and high expression of NK cell activation receptors and high purity, which makes...

 January 23, 2024 | News

Japan greenlights historic treatment for ultra-rare Progeria, marking a significant breakthrough in addressing rapid-aging diseases.

The Progeria Research Foundation (PRF) today announced a new milestone with the approval of Zokinvy™ (lonafarnib) by the Japanese Ministry of Health,...

 January 22, 2024 | News

Epitomee® Successfully Completes Pivotal Trial for Innovative Weight Loss Capsule

The primary objective of the RESET trial was to collect data to support a planned FDA regulatory submission, paving the way for the marketing and distribut...

 January 17, 2024 | News

CARsgen's CT011 Granted NMPA IND Clearance for GPC3-Positive Stage Ⅲa Liver Cancer

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignan...

 January 16, 2024 | News

Australia Achieves Positive Results in Phase Ib Study for Androgenic Alopecia Treatment

This study is led by Professor Rodney Sinclair and included 12 male and 4 female patients in Australia with androgenic alopecia (AGA). ...

 January 15, 2024 | News

Renovion Finishes Adult Patient Enrollment in Phase 2 CLIMB Study for Bronchiectasis

CLIMB is a US based, randomized, double-blind, placebo-controlled Phase 2 study to evaluate the safety, tolerability and efficacy of ARINA-1 in participant...

 January 12, 2024 | News

Teva Completes Recruitment for Phase 3 Study of MedinCell's mdc-TJK/Olanzapine LAI

mdc-TJK is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophrenia. ...

 January 11, 2024 | News

Medidata Tops Everest Group's Decentralized Clinical Trial Platforms PEAK Matrix®

-Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, has again been recognized as ...

 January 10, 2024 | News

Menarini Silicon Biosystems Publishes DETECT III Trial Results on HER2 Testing in Circulating Tumor Cells with CELLSEARCH

Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced today the publication, in the Journal of Clinical Chemistry, of the fina...

 January 10, 2024 | News

GC Cell Initiates Phase 1 Trials for AB-201 Cancer Treatment with Lunit AI Platform

 GC Cell, a fully integrated cell therapy pioneer, is proud to announce the approval from both the Australian Human Research Ethics Committee (HREC) a...

 January 09, 2024 | News

OBI Pharma's partner Biosion announces FDA clearance for the Phase 1/2 study of OBI-992 (TROP2 ADC)

First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2 - Dosing of f...

 January 09, 2024 | News

Caliway's CBL-514 IND for Dercum's Disease Phase 2 Study Accepted by FDA

Dercum's disease is a rare disease characterized by the growth of painful lipomas. The pain can be severe, chronic (> 3 months) and often disabling. So ...

 January 09, 2024 | News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in